马蔺子素对鼻咽癌放射治疗的影响

目的探讨马蔺子素(安卡)对鼻咽癌放射治疗的增敏作用及不良反应。方法158例经病理证实为鼻咽癌的患者随机分为马蔺子素联合放射治疗组(治疗组)和单纯放射治疗组(对照组),两组放射治疗方法、剂量相同,治疗组在放射治疗的同时服用安卡110mg/次,每天2次,直至放射治疗结束。采用增敏比(SER)和肿瘤的局部控制率(PR、CR)作为增敏的评价指标。根据全消率剂量曲线分析增敏效应的特征。结果鼻咽部和颈部转移病灶在达到PR和CR时的平均剂量,治疗组均明显低于对照组(P<001),增敏比为106～124,治疗结束时原发灶和颈部转移灶的CR率治疗组明显高于对照组(P<005和P<001)。当放射治疗剂量达30Gy后两组疗效开始出现差别,随着剂量的递增差别渐扩大。治疗组出现较多的恶心呕吐、腹泻等消化道反应(P<005)。照射野内正常组织未见明显增敏现象。结论马蔺子素对鼻咽癌原发灶和颈部转移灶均有明显的放射增敏作用。

Combination of irisquinone and radiation therapy for nasopharyngeal carcinoma

Objective To study the radiosensitization and toxicity of irisquinone in combination with radiotherapy in patients with nasopharyngeal carcinoma(NPC).Methods 158 cases of pathological proven NPC were divided at random into study group and control group.The dosage and method of radiation were identical in the two groups.The patients of study group were treated with radiotherapy combined with irisquinone 110mg twice daily through treatment.Sensitization enhancement ratio(SER) and local control of carcinoma(PR,CR) were used to evaluate the radiosensitization of irisquinone.And the character of enhancement ratio effect was analyzed by disappearance rate-dosage graph.Results Whether primary or metastatic focus,the average radiation dosage of PR and CR in the study group were lower than those in control group(P<0.01).SER was between 1.06 and 1.24.CR rate of primary or metastatic focus was superior to that in control group at the end of the treatment(P<0.05 and P<0.01).When the dosage reached 30Gy,the efficacy showed difference in the study group and the control group.With the dosage increasing,it had greater difference.Patients in the study group had more gastrointestinal side-effects such as nausea,vomiting and diarrhea.The normal tissue in irradiation portals did not show any radiosensitization.Conclusion This study confirmed that irisquinone has radiosensitive effect in the treatment of primary tumor for patients with NPC as well as in the treatment of metastatic tumor for patients with NPC.